HIGHLIGHTS
- who: Sarah Kru00f6ller and collaborators from the Ghent University Hospital, Belgium Hannover Medical School, Germany have published the paper: Brutonu2019s tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome, in the Journal: (JOURNAL)
- what: The authors report for the first time that the two FDA-approved BTKi ibrutinib and acalabrutinib attenuate disease progression seen by a reduction of renal immune cell infiltration in a murine model of HUS. In the present study, ibrutinib-treated mice with HUS showed positive impact on hemolysis while intervention with acalabrutinib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.